Skip to main content
SpringerLink
Log in

Acetyl-L-Carnitine in HIV-Associated Antiretroviral Toxic Neuropathy

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Nucleoside analogue reverse transcriptase inhibitors (NRTIs), used as part of highly active antiretroviral therapy for the treatment of HIV and AIDS, disrupt neuronal mitochondrial DNA synthesis, resulting in antiretroviral toxic neuropathy (ATN). Acetyl-L-carnitine (ALC) enhances neurotrophic support of sensory neurons, potentially causing symptom relief and nerve regeneration, and in addition has numerous other effects on metabolic function that might be of benefit in such patients.

ALC has been given to HIV patients with symptomatic ATN in a number of clinical studies administered either twice daily intramuscularly or as oral sachets or tablets. It has been shown to significantly reduce a variety of validated pain ratings, and is generally safe and well tolerated. Using a measure of neuronal innervation in standardised skin biopsies of the affected area, cutaneous nerve density has been improved by the administration of ALC in subjects with symptomatic ATN and reduced epidermal and dermal innervation, associated with clinical improvement, which was maintained over a 4-year period. Improvements were seen in both the structure and function of small sensory fibres, which were sustained over time whilst subjects received ALC. Other open-label, non-randomised studies have shown similar benefits in patients with ATN in terms of pain reduction over the short term.

Further placebo-controlled studies of both treatment and prophylaxis have been completed and are under analysis to characterise further the usefulness of this pathogenesis-based therapy for ATN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9(2): 153–61

    CAS  PubMed  Google Scholar 

  2. Hall CD, Snyder CR, Messenheimer JA, et al. Peripheral neuropathy in a cohort of human immunodeficiency virus-infected patients: incidence and relationship to other nervous system dysfunction. Arch Neurol 1991; 48(12): 1273–4

    Article  CAS  PubMed  Google Scholar 

  3. Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection: AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998; 51(6): 1682–8

    Article  CAS  PubMed  Google Scholar 

  4. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19(6): 481–94

    Article  CAS  PubMed  Google Scholar 

  5. Moore RD, Wong WM, Keruly JC, et al. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000; 14(3): 273–8

    Article  CAS  PubMed  Google Scholar 

  6. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12(14): 1735–44

    Article  CAS  PubMed  Google Scholar 

  7. Baril JG, Pollard RB, Raffi F, et al. Stavudine extended/prolonged release (XR/PRC) vs stavudine immediate release in combination with lamivudine and efavirenz: 48 week efficacy and safety [abstract no. LbPeB9014]. Fourteenth International AIDS Conference; 2002 Jul 7–12; Barcelona

  8. Simpson DM, Haidich AB, Schifitto G, et al. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS 2002; 16(3): 407–12

    Article  CAS  PubMed  Google Scholar 

  9. Hahn K, Arendt G, Braun JS, et al. for the German Neuro-AIDS Working Group. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004; 251(10): 1260–6

    CAS  PubMed  Google Scholar 

  10. McArthur JC, Yiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000; 54(5): 1080–8

    CAS  Google Scholar 

  11. Gazzard BG. on behalf of the BHIVA Guidelines Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006 Nov; 7(8): 487–503

    CAS  PubMed  Google Scholar 

  12. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39(5): 625–8

    CAS  PubMed  Google Scholar 

  13. Keilbaugh SA, Prusoff WH, Simpson MV. The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside analogs. Biochem Pharmacol 1991; 42(1): R5–8

    Article  CAS  PubMed  Google Scholar 

  14. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1(5): 417–22

    Article  CAS  PubMed  Google Scholar 

  15. McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995; 45(10): 1848–55

    Article  CAS  PubMed  Google Scholar 

  16. Polydefkis M, Yiannoutsos CT, Cohen BA, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology 2002; 58(1): 115–9

    Article  CAS  PubMed  Google Scholar 

  17. Hart AM, Wilson ADH, Montovani C, et al. Acetyl-1-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004; 18: 1549–60

    Article  CAS  PubMed  Google Scholar 

  18. Cunningham WE, Shapiro MF, Hays RD, et al. Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease. Am J Med 1998; 104(2): 129–36

    Article  CAS  PubMed  Google Scholar 

  19. Bremer J. The role of carnitine in intracellular metabolism. J Clin Chem Clin Biochem 1990; 28(5): 297–301

    CAS  PubMed  Google Scholar 

  20. Colucci WJ, Grandour RD. Carnitine acyltransferase: a review of its biology, enzymology and bioorganic chemistry. Bioorg Chem 1988; 16: 307–34

    Article  CAS  Google Scholar 

  21. Gorio A, Di Giulio AM, Tenconi B. Peptide alteration in autonomic diabetic neuropathy prevented by acetyl-L-carnitine. Int J Clin Pharmacol Res 1992; 12: 225–30

    CAS  PubMed  Google Scholar 

  22. Manfridi A, Forloni GL, Arrigoni-Martelli E, et al. Culture of dorsal root ganglion neurons from aged rats: effects of acetyl-L-carnitine and NGF. Int J Dev Neurosci 1992; 10(4): 321–9

    Article  CAS  PubMed  Google Scholar 

  23. Rampello L, Giammona G, Aleppo MG. Trophic action of acetyl-L-carnitine in neuronal cultures. Acta Neurol 1992; 14: 15–21

    CAS  Google Scholar 

  24. White HL, Scates PW. Stimulation of carnitine acetyltransferase in PC12 cells by nerve growth factor: relationship to choline acetyltransferase stimulation. Neurochem Res 1991; 16: 63–6

    Article  CAS  PubMed  Google Scholar 

  25. Arienti A, Ramacii MT, Maccari F. Acetyl-L-carnitine influences the fluidity of brain microsomes and of liposomes made of rat brain microsomal extracts. Neurochem Res 1992; 17: 671–5

    Article  CAS  PubMed  Google Scholar 

  26. Taglialatela G, Angelucci L, Ramacci MT, et al. Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor. Brain Res Dev Brain Res 1991; 59(2): 221–30

    Article  CAS  PubMed  Google Scholar 

  27. Angelucci L, Ramacci MT, Taglialatela G, et al. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neurosci Res 1988; 20(4): 491–6

    Article  CAS  PubMed  Google Scholar 

  28. Fernandez E, Pallini R, Gangitano C, et al. Effects of L-carnitine, L-acetylcarnitine and gangliosides on the regeneration of the transected sciatic nerve in rats. Neurol Res 1989; 11(1): 57–62

    Article  CAS  PubMed  Google Scholar 

  29. Hart AM, Wiberg M, Terenghi G. Pharmacological enhancement of peripheral nerve regeneration in the rat by systemic acetyl-L-carnitine treatment. Neurosci Lett 2002; 334: 181–5

    Article  Google Scholar 

  30. Virmani MA, Biselli R, Spadoni A, et al. Protective actions of L-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol Res 1995; 32(6): 383–9

    Article  CAS  PubMed  Google Scholar 

  31. Hart AM, Wiberg M, Youle M, et al. Systemic acetyl-L-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma. Exp Brain Res 2002; 145(2): 182–9

    Article  CAS  PubMed  Google Scholar 

  32. Sima AA, Ristic H, Merry A, et al. Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 1996; 97(8): 1900–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Chiechio S, Caricasole A, Barletta E, et al. L-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol Pharmacol 2002; 61: 1–8

    Article  Google Scholar 

  34. Ghelardini C, Galeotti N, Calvani M, et al. Acetyl-L-carnitine induces muscarinic antinociception in mice and rats. Neuropharmacology 2002; 43(7): 1180–7

    Article  CAS  PubMed  Google Scholar 

  35. Galeotti N, Bartolini A, Calvani M, et al. Acetyl-L-carnitine requires phospholipase C-IP3 pathway activation to induce antinociception. Neuropharmacology 2004; 47(2): 286–94

    Article  CAS  PubMed  Google Scholar 

  36. Chiechio S, Copani A, Melchiorri D, et al. Metabotropic receptors as target for drugs of potential use in the treatment of neuropathic pain. J Endocrinol Invest 2004; 27(6): 171–6

    CAS  PubMed  Google Scholar 

  37. Onofrj M, Fulgente T, Melchionda D, et al. L-Acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. Int J Clin Pharmacol Res 1995; 15(1): 9–15

    CAS  PubMed  Google Scholar 

  38. De Grandis D, Minardi C. Acetyl-L-carnitine (levacarnine) in the treatment of diabetic neuropathy: a long-term randomized, double-blind, placebo controlled study. Drugs RD 2002; 3(4): 223–31

    Article  CAS  Google Scholar 

  39. Lal L, Wesselingh S, Tachedjian G, et al. L-Acetyl carnitine prevents antiretroviral toxic neuropathy in an in vitro model [abstract no. 369]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)

  40. Scarpini E, Sacilotto G, Baron P, et al. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst 1997; 2(3): 250–2

    CAS  PubMed  Google Scholar 

  41. De Grandis D. Tolerability and efficacy of L-acetylcarnitine in patients with peripheral neuropathies: a short-term, open multicentre study. Clin Drug Invest 1998; 15(2): 73–9

    Article  CAS  Google Scholar 

  42. Herzmann C, Johnson M, Youle M. Lon-term effect of acetyl-Lcarnitine for antiretroviral toxic neuropathy. HIV Clin Trials 2005; 6(6): 344–50

    Article  PubMed  Google Scholar 

  43. Osio M, Muscia F, Zampini L, et al. Acetyl-L-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J PeriphNerve System 2006; 11: 72–6

    CAS  Google Scholar 

  44. Youle M, Osio M; ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007; 8(4): 241–50

    Article  CAS  PubMed  Google Scholar 

  45. Adle-Biassette H, Bell JE, Creange A, et al. DNA breaks detected by in situ end-labelling in dorsal root ganglia of patients with AIDS. Neuropathol Appl Neurobiol 1998; 24(5): 373–80

    Article  CAS  PubMed  Google Scholar 

  46. Calvani M, Arrigoni-Martelli E. Attenuation by Acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React 1999; 21(1): 1–6

    CAS  PubMed  Google Scholar 

  47. Peluso G, Benatti P, Nicolai R, et al. Carnitine system and insulin resistence. In: Crepaldi G, Tiengo A, Del Prato S, editors. Insulin resistance, metabolic disease and diabetic complications. London: Elsevier, 1998: 259–74

    Google Scholar 

  48. De Grandis D, Santoro L, Di Benedetto P. L-Acetylcarnitine in the treatment of patients with peripheral neuropathies. Clin Drug Invest 1995; 10: 317–22

    Article  CAS  Google Scholar 

  49. Giammusso B, Morgia G, Spampinto A, et al. Improved pallesthetic sensitivity of pudendal nerve in impotent diabetic patients treated with acetyl-L-carnitine. Acta Urol Ital 1996; 10: 185–7

    Google Scholar 

  50. Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 1997; 11(2): 185–90

    Article  CAS  PubMed  Google Scholar 

  51. Parnetti L, Gaiti A, Mecocci P, et al. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol 1992; 42(1): 89–93

    Article  CAS  PubMed  Google Scholar 

  52. Marzo A, Arrigoni Martelli E, et al. Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers. Eur J Clin Pharmacol 1989; 37(1): 59–63

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Source of support: Sigma-Tau Farmaceutiche Riunite S.p.A., Pomezia, Rome, Italy

Conflict of interest: Dr Youle has received travel bursaries from Sigma-Tau to attend scientific meetings.

Author information

Authors and Affiliations

  1. Royal Free Centre for HIV Medicine, Royal Free Hospital, Pond Street, London, NW3 2QG, UK

    Mike Youle

Authors
  1. Mike Youle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mike Youle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Youle, M. Acetyl-L-Carnitine in HIV-Associated Antiretroviral Toxic Neuropathy. CNS Drugs 21 (Suppl 1), 25–30 (2007). https://doi.org/10.2165/00023210-200721001-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721001-00004

Keywords

Search

Navigation